364 related articles for article (PubMed ID: 27160864)
1. The alternative pathway of complement and the thrombotic microangiopathies.
Teoh CW; Riedl M; Licht C
Transfus Apher Sci; 2016 Apr; 54(2):220-31. PubMed ID: 27160864
[TBL] [Abstract][Full Text] [Related]
2. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
Schmidtko J; Peine S; El-Housseini Y; Pascual M; Meier P
Am J Kidney Dis; 2013 Feb; 61(2):289-99. PubMed ID: 23141475
[TBL] [Abstract][Full Text] [Related]
3. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].
Kistler AD
Praxis (Bern 1994); 2016 Mar; 105(7):389-96. PubMed ID: 27005733
[TBL] [Abstract][Full Text] [Related]
4. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.
Sridharan M; Go RS; Willrich MAV
J Immunol Methods; 2018 Oct; 461():15-22. PubMed ID: 30031798
[TBL] [Abstract][Full Text] [Related]
5. Complement Activation and Thrombotic Microangiopathies.
Palomo M; Blasco M; Molina P; Lozano M; Praga M; Torramade-Moix S; Martinez-Sanchez J; Cid J; Escolar G; Carreras E; Paules C; Crispi F; Quintana LF; Poch E; Rodas L; Goma E; Morelle J; Espinosa M; Morales E; Avila A; Cabello V; Ariceta G; Chocron S; Manrique J; Barros X; Martin N; Huerta A; Fraga-Rodriguez GM; Cao M; Martin M; Romera AM; Moreso F; Manonelles A; Gratacos E; Pereira A; Campistol JM; Diaz-Ricart M
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1719-1732. PubMed ID: 31694864
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic microangiopathies.
Rosove MH
Semin Arthritis Rheum; 2014 Jun; 43(6):797-805. PubMed ID: 24360024
[TBL] [Abstract][Full Text] [Related]
7. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
8. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option.
Román E; Mendizábal S; Jarque I; de la Rubia J; Sempere A; Morales E; Praga M; Ávila A; Górriz JL
Nefrologia; 2017; 37(5):478-491. PubMed ID: 28946961
[TBL] [Abstract][Full Text] [Related]
9. [The revolution of monoclonal antibodies in the treatment of thrombotic microangiopathy].
Sauvètre G; Grange S; Froissart A; Veyradier A; Coppo P; Benhamou Y
Rev Med Interne; 2015 May; 36(5):328-38. PubMed ID: 25547956
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
Risitano AM; Marotta S
Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
[TBL] [Abstract][Full Text] [Related]
11. What is the evidence for the role of therapeutic apheresis in the management of complement-associated thrombotic microangiopathies?
Yıldız S; Demirkan F
Transfus Apher Sci; 2018 Feb; 57(1):31-34. PubMed ID: 29506907
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding.
Fujita Y; Terashita M; Yazawa M; Yamasaki Y; Imamura T; Kibayashi J; Sawai T; Hidaka Y; Ohtani K; Inoue N; Shibagaki Y
Intern Med; 2020; 59(1):93-99. PubMed ID: 31902910
[TBL] [Abstract][Full Text] [Related]
13. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
14. Thrombotic Microangiopathy in Cancer.
Weitz IC
Semin Thromb Hemost; 2019 Jun; 45(4):348-353. PubMed ID: 31041804
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
Wright RD; Bannerman F; Beresford MW; Oni L
BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report.
Chandran S; Baxter-Lowe L; Olson JL; Tomlanovich SJ; Webber A
Transplant Proc; 2011 Jun; 43(5):2097-101. PubMed ID: 21693335
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
18. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.
de Holanda MI; Pôrto LC; Wagner T; Christiani LF; Palma LMP
Clin Rheumatol; 2017 Dec; 36(12):2859-2867. PubMed ID: 28905254
[TBL] [Abstract][Full Text] [Related]
19. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment.
Raina R; Krishnappa V; Blaha T; Kann T; Hein W; Burke L; Bagga A
Ther Apher Dial; 2019 Feb; 23(1):4-21. PubMed ID: 30294946
[TBL] [Abstract][Full Text] [Related]
20. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.
Sevinc M; Basturk T; Sahutoglu T; Sakaci T; Koc Y; Ahbap E; Akgol C; Kara E; Brocklebank V; Goodship TH; Kavanagh D; Unsal A
J Med Case Rep; 2015 Apr; 9():92. PubMed ID: 25925370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]